What's new

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 22, Status: Authorised

Mar 25, 2025 - 17:21
 0
Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 22, Status: Authorised
Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 22, Status: Authorised
Read More

Tags:

Previous Article

Novo Nordisk follows Eli Lilly with its own ‘triple-G’ drug

Next Article

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, D...

Related Posts

European shortages monitoring platform (ESMP) API - Req...

Mar 27, 2025  0

Questions and answers on implementation of the medical ...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Date of authorisation: 14/02/1996, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 17, 2025  0